Search

Your search keyword '"Mestecky, Jiri"' showing total 308 results
Start Over Author "Mestecky, Jiri" Search Limiters Full Text
308 results on '"Mestecky, Jiri"'

1. Secretory IgA N-glycans contribute to the protection against E. coli O55 infection of germ-free piglets

Author

Raskova Kafkova, Leona, Brokesova, Diana, Krupka, Michal, Stehlikova, Zuzana, Dvorak, Jiri, Coufal, Stepan, Fajstova, Alena, Srutkova, Dagmar, Stepanova, Katerina, Hermanova, Petra, Stepankova, Renata, Uberall, Ivo, Skarda, Jozef, Novak, Zdenek, Vannucci, Luca, Tlaskalova-Hogenova, Helena, Jiraskova Zakostelska, Zuzana, Sinkora, Marek, Mestecky, Jiri, and Raska, Milan

Published
2021
Full Text
View/download PDF

3. The Neonatal Fc Receptor (FcRn) Enhances Human Immunodeficiency Virus Type 1 (HIV-1) Transcytosis across Epithelial Cells

Author

Gupta, Sandeep, Gach, Johannes S, Becerra, Juan C, Phan, Tran B, Pudney, Jeffrey, Moldoveanu, Zina, Joseph, Sarah B, Landucci, Gary, Supnet, Medalyn Jude, Ping, Li-Hua, Corti, Davide, Moldt, Brian, Hel, Zdenek, Lanzavecchia, Antonio, Ruprecht, Ruth M, Burton, Dennis R, Mestecky, Jiri, Anderson, Deborah J, Forthal, Donald N, and Desrosiers, Ronald C

Subjects
Antibody-Dependent Enhancement, Female Genital-Tract, Monoclonal-Antibodies, Dendritic Cells, Hiv-1-Infected Individuals, 1-Infected Individuals, Mediated Presentation, Cervical Ectopy, Human Placenta, Vaginal Ph
Published
2013

6. Mucosal immunity: The missing link in comprehending SARS-CoV-2 infection and transmission

Author

Russell, Michael W. and Mestecky, Jiri

Subjects
Mice, SARS-CoV-2, Immunoglobulin A, Secretory, Immunology, Animals, COVID-19, Humans, Immunology and Allergy, Immunity, Mucosal, Administration, Intranasal
Abstract

SARS-CoV-2 is primarily an airborne infection of the upper respiratory tract, which on reaching the lungs causes the severe acute respiratory disease, COVID-19. Its first contact with the immune system, likely through the nasal passages and Waldeyer’s ring of tonsils and adenoids, induces mucosal immune responses revealed by the production of secretory IgA (SIgA) antibodies in saliva, nasal fluid, tears, and other secretions within 4 days of infection. Evidence is accumulating that these responses might limit the virus to the upper respiratory tract resulting in asymptomatic infection or only mild disease. The injectable systemic vaccines that have been successfully developed to prevent serious disease and its consequences do not induce antibodies in mucosal secretions of naïve subjects, but they may recall SIgA antibody responses in secretions of previously infected subjects, thereby helping to explain enhanced resistance to repeated (breakthrough) infection. While many intranasally administered COVID vaccines have been found to induce potentially protective immune responses in experimental animals such as mice, few have demonstrated similar success in humans. Intranasal vaccines should have advantage over injectable vaccines in inducing SIgA antibodies in upper respiratory and oral secretions that would not only prevent initial acquisition of the virus, but also suppress community spreadviaaerosols and droplets generated from these secretions.

Published
2022
Full Text
View/download PDF

8. Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors

Author

Zachova, Katerina, primary, Jemelkova, Jana, additional, Kosztyu, Petr, additional, Ohyama, Yukako, additional, Takahashi, Kazuo, additional, Zadrazil, Josef, additional, Orsag, Jiri, additional, Matousovic, Karel, additional, Galuszkova, Dana, additional, Petejova, Nadezda, additional, Mestecky, Jiri, additional, and Raska, Milan, additional

Published
2022
Full Text
View/download PDF

10. Comparison of Systemic and Mucosal Delivery of 2 Canarypox Virus Vaccines Expressing Either HIV-1 Genes or the Gene for Rabies Virus G Protein

Author

The National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group, Wright, Peter F., Mestecky, Jiri, McElrath, M. Juliana, Keefer, Michael C., Gorse, Geoffrey J., Goepfert, Paul A., Moldoveanu, Zina, Schwartz, David, Spearman, Paul W., El Habib, Raphaelle, Spring, Michele D., Zhu, Yuwei, Smith, Carol, Flores, Jorge, and Weinhold, Kent J.

Published
2004

21. Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing $HIV-1_mn$ gpl20, $HIV-1_SF2$ Recombinant gp120, or Both Vaccines in Seronegative Adults

Author

NIAID AIDS Vaccine Evaluation Group, Clements-Mann, Mary Lou, Weinhold, Kent, Matthews, Thomas J., Graham, Barney S., Gorse, Geoffrey J., Keefer, Michael C., McElrath, M. Juliana, Hsieh, Ray-Hahn, Mestecky, Jiri, Zolla-Pazner, Susan, Mascola, John, Schwartz, David, Siliciano, Robert, Corey, Lawrence, Wright, Peter F., Belshe, Robert, Dolin, Raphael, Jackson, Susan, Xu, Serena, Fast, Patricia, Walker, Mary Clare, Stablein, Don, Excler, Jean-Louis, Tartaglia, James, Duliege, Anne-Marie, Sinangil, Faruk, and Paoletti, Enzo

Published
1998

22. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity

Author

Suzuki, Hitoshi, Fan, Run, Zhang, Zhixin, Brown, Rhubell, Hall, Stacy, Julian, Bruce A., Chatham, W. Winn, Suzuki, Yusuke, Wyatt, Robert J., Moldoveanu, Zina, Lee, Jeannette Y., Robinson, James, Tomana, Milan, Tomino, Yasuhiko, Mestecky, Jiri, and Novak, Jan

Subjects
Diagnosis, Care and treatment, Prevention, Physiological aspects, Research, Health aspects, Glycosylation -- Physiological aspects -- Research -- Health aspects, Immune complexes -- Health aspects -- Research -- Physiological aspects, Iga glomerulonephritis -- Diagnosis -- Care and treatment -- Prevention -- Research, IgA glomerulonephritis -- Diagnosis -- Care and treatment -- Prevention -- Research
Abstract

Introduction IgA nephropathy (IgAN), also called Berger disease, was described in 1968 (1) based on the immunohistochemical finding of IgA- and IgG-containing immune complexes in the glomerular mesangium of the [...], IgA nephropathy (IgAN) is characterized by circulating immune complexes composed of galactose-deficient IgA1 and a glycan-specific IgG antibody. These immune complexes deposit in the glomerular mesangium and induce the mesangioproliferative glomerulonephritis characteristic of IgAN. To define the precise specificities and molecular properties of the IgG antibodies, we generated EBV-immortalized IgG-secreting lymphocytes from patients with IgAN and found that the secreted IgG formed complexes with galactose-deficient IgA1 in a glycan-dependent manner. We cloned and sequenced the heavy- and light-chain antigen-binding domains of IgG specific for galactose-deficient IgA1 and identified an A to S substitution in the complementarity-determining region 3 of the variable region of the gene encoding the IgG heavy chain in IgAN patients. Furthermore, site-directed mutagenesis that reverted the residue to alanine reduced the binding of recombinant IgG to galactose-deficient IgA1. Finally, we developed a dot-blot assay for the glycan-specific IgG antibody that differentiated patients with IgAN from healthy and disease controls with 88% specificity and 95% sensitivity and found that elevated levels of this antibody in the sera of patients with IgAN correlated with proteinuria. Collectively, these findings indicate that glycan-specific antibodies are associated with the development of IgAN and may represent a disease-specific marker and potential therapeutic target.

Published
2009

23. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1

Author

Suzuki, Hitoshi, Moldoveanu, Zina, Hall, Stacy, Brown, Rhubell, Vu, Huong L., Novak, Lea, Julian, Bruce A., Tomana, Milan, Wyatt, Robert J., Edberg, Jeffrey C., Alarcon, Graciela S., Kimberly, Robert P., Tomino, Yasuhiko, Mestecky, Jiri, and Novak, Jan

Subjects
Care and treatment, Research, Risk factors, Health aspects, Glycosylation -- Health aspects -- Research, Iga glomerulonephritis -- Risk factors -- Care and treatment -- Research, Immunoglobulin A -- Health aspects -- Research, IgA glomerulonephritis -- Risk factors -- Care and treatment -- Research
Abstract

Introduction IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide (1), with about 20%-40% of patients developing end-stage renal failure. IgAN is defined by the dominance or codominance of [...], Aberrant glycosylation of IgA1 plays an essential role in the pathogenesis of IgA nephropathy. This abnormality is manifested by a deficiency of galactose in the hinge-region O-linked glycans of IgA1. Biosynthesis of these glycans occurs in a stepwise fashion beginning with the addition of N-acetylgalactosamine by the enzyme N-acetylgalactosaminyltransferase 2 and continuing with the addition of either galactose by β1,3-galactosyltransferase or a terminal sialic acid by a N-acetylgalactosamine--specific α2,6-sialyltransferase. To identify the molecular basis for the aberrant IgA glycosylation, we established EBV-immortalized IgA1-producing cells from peripheral blood cells of patients with IgA nephropathy. The secreted IgA1 was mostly polymeric and had galactose-deficient O-linked glycans, characterized by a terminal or sialylated N-acetylgalactosamine. As controls, we showed that EBV-immortalized cells from patients with lupus nephritis and healthy individuals did not produce IgA with the defective galactosylation pattern. Analysis of the biosynthetic pathways in cloned EBV-immortalized cells from patients with IgA nephropathy indicated a decrease in β1,3-galactosyltransferase activity and an increase in N-acetylgalactosamine--specific α2,6-sialyltransferase activity. Also, expression of β1,3-galactosyltransferase was significantly lower, and that of N-acetylgalactosamine--specific α2,6-sialyltransferase was significantly higher than the expression of these genes in the control cells. Thus, our data suggest that premature sialylation likely contributes to the aberrant IgA1 glycosylation in IgA nephropathy and may represent a new therapeutic target.

Published
2008

29. The Pathophysiology of IgA Nephropathy

Author

Suzuki, Hitoshi, Kiryluk, Krzysztof, Novak, Jan, Moldoveanu, Zina, Herr, Andrew B., Renfrow, Matthew B., Wyatt, Robert J., Scolari, Francesco, Mestecky, Jiri, Gharavi, Ali G., and Julian, Bruce A.

Published
2011
Full Text
View/download PDF

31. Multiparametric flow cytometry analysis of peripheral blood B cell trafficking differences among Epstein-Barr virus infected and uninfected subpopulations

Author

Zachova, Katerina, primary, Kosztyu, Petr, additional, Zadrazil, Josef, additional, Matousovic, Karel, additional, Vondrak, Karel, additional, Hubacek, Petr, additional, Kostovcikova, Klara, additional, Tlaskalova Hogenova, Helena, additional, Mestecky, Jiri, additional, and Raska, Milan, additional

Published
2020
Full Text
View/download PDF

37. Vitamin A is required for regulation of polymeric immunoglobulin receptor (plgR) expression by interleukin-4 and interferon-gamma in a human intestinal epithelial cell line

Author

Sarkar, Jolly, Gangopadhyay, Nupur N., Moldoveanu, Zina, Mestecky, Jiri, and Stephenson, Charles B.

Subjects
Vitamin A in human nutrition -- Research, Antibodies -- Research, Food/cooking/nutrition
Abstract

The secretory immunoglobulin A (IgA) antibody response to infections of mucosal surfaces requires transport of IgA from the basal to apical surface of mucosal epithelial cells by a specific transport protein, the polymeric immunoglobulin receptor (plgR). We have tested the hypothesis that the vitamin A metabolite all-trans retinoic acid (RA) is required for the regulation of plgR expression by the cytokines interleukin-4 (IL-4) and interferon-[Gamma] (IFN-[Gamma]) in HT-29 cells, a well-differentiated human epithelial cell line derived from a colonic carcinoma. plgR expression is upregulated by IFN-[Gamma] and IL-4 when HT-29 cells are grown in normal media, but this upregulation was significantly lower when cells were grown in vitamin A-depleted media. Treatment with RA at concentrations from [10.sup.-9] to [10.sup.-5] mol/L restored normal levels of plgR expression. The percentages of cells expressing cell-surface plgR after 24, 48 and 72 h of treatment with RA, IL-4 and IFN-[Gamma] were 66 [+ or -] 10, 90 [+ or -] 5 and 92 [+ or -] 1, respectively, significantly higher than the percentages seen without RA treatment, which were 32 [+ or -] 2.3, 72 [+ or -] 1.2 and 30 [+ or -] 7, respectively. In addition, the intensity of fluorescence of plgR-positive cells was significantly higher in the RA-treated cultures than in the cultures without RA treatment. Similarly, plgR mRNA levels (adjusted for [Beta]-actin mRNA levels) in RA-supplemented cultures were 404, 105 and 949% higher at 24, 48 and 72 h, respectively, than were plgR mRNA levels in identical cultures grown in the absence of RA. These data indicate that RA strongly interacts with IL-4 and IFN-[Gamma] to regulate plgR expression in HT-29 cells, suggesting that vitamin A may be required for proper in vivo regulation of IgA transport in response to mucosal infections. KEY WORDS: vitamin A; retinoic acid; transporters; humans; antibodies

Published
1998

44. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein

Author

Wright, Peter F., Mestecky, Jiri, McElrath, M. Juliana, Keefer, Michael C., Gorse, Geoffrey J., Goepfert, Paul A., Moldoveanu, Zina, Schwartz, David, Spearman, Paul W., El Habib, Raphaelle, Spring, Michele D., Zhu, Yuwei, Smith, Carol, Flores, Jorge, and Weinhold, Kent J.

Subjects
T cells -- Health aspects, Rabies vaccines -- Health aspects, HIV infection -- Care and treatment, HIV infection -- Research, Health
Published
2004

Catalog

Books, media, physical & digital resources
See catalog results